Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Insulin (Oramed) in Diabetes Mellitus, Type 2: NCT04618744 Clinical Landscape Report 2026
16 October 2026
NCT04618744 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lidocaine in Vaso-occlusive crisis: NCT04614610 Clinical Landscape Report 2026
16 October 2026
NCT04614610 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inclacumab in Hematologic Diseases: ACTRN12620001156976 Clinical Landscape Report 2026
16 October 2026
ACTRN12620001156976 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Anemia, Sickle Cell: NCT04624659 Clinical Landscape Report 2026
16 October 2026
NCT04624659 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Diabetes Mellitus, Type 2: NCT04639414 Clinical Landscape Report 2026
16 October 2026
NCT04639414 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Danazol in Dyskeratosis Congenita: NCT04638517 Clinical Landscape Report 2026
16 October 2026
NCT04638517 clinical landscape for Dyskeratosis Congenita: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Resmetirom in Hepatic Insufficiency: NCT04643795 Clinical Landscape Report 2026
16 October 2026
NCT04643795 clinical landscape for Hepatic Insufficiency: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Crizanlizumab-TMCA in Anemia, Sickle Cell: NCT04657822 Clinical Landscape Report 2026
16 October 2026
NCT04657822 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ORIN-1001 in Idiopathic Pulmonary Fibrosis: NCT04643769 Clinical Landscape Report 2026
16 October 2026
NCT04643769 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efanesoctocog alfa in Hemophilia A: NCT04644575 Clinical Landscape Report 2026
16 October 2026
NCT04644575 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Coagulation factor VIIa (recombinant)-jncw(LFB Biotechnologies SASU) in Hemorrhage: NCT04647227 Clinical Landscape Report 2026
16 October 2026
NCT04647227 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rozanolixizumab in Myasthenia Gravis: NCT04650854 Clinical Landscape Report 2026
16 October 2026
NCT04650854 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.